EPOCH, which began in late 2012, sought to improve Alzheimer’s disease symptoms by slowing deposition of the beta-amyloid plaques characteristic of AD. The first step in beta-amyloid production requires a BACE enzyme. This study tested verubecestat, an inhibitor of one such BACE enzyme, in patients with mild-to-moderate Alzheimer’s disease.